Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Kensei Yamaguchi,Yung-Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kohei Shitara

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

2021

Kensei Yamaguchi
Yung-Jue Bang
Satoru Iwasa
Naotoshi Sugimoto
Min-Hee Ryu
Daisuke Sakai
Hyun Cheol Chung
Hisato Kawakami
Hiroshi Yabusaki
Jeeyun Lee
Kaku Saito
Yoshinori Kawaguchi
Takahiro Kamio
Akihito Kojima
Masahiro Sugihara
Kohei Shitara

4048Background: T-DXd is an antibody–drug conjugate comprising an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor. DESTINY-Gastric01 (DS8201-A-J202; Clini...

Keywords:

Topoisomerase-I Inhibitor
Linker
Adenocarcinoma
Medicine
Trastuzumab
Conjugate
Phases of clinical research
Tetrapeptide
Cancer research
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations